These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11069868)

  • 1. Screening travelers for hepatitis A antibodies: an observational cost-comparison study of vaccine use.
    Lee KK; Beyer-Blodget J
    West J Med; 2000 Nov; 173(5):325-9. PubMed ID: 11069868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The efficacy of the prevaccination detection of anti-HAV in hepatitis A vaccination programs].
    Navas E; Bayas JM; Bruguera M; Vidal J; Galí N; Taberner JL; Salleras L
    Med Clin (Barc); 1995 Jul; 105(5):168-71. PubMed ID: 7630228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination.
    Schwartz E; Raveh D
    Int J Epidemiol; 1998 Feb; 27(1):118-20. PubMed ID: 9563704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination strategies against hepatitis A in travelers older than 40 years: an economic evaluation.
    Costas L; Vilella A; Trilla A; Serrano B; Vera I; Roldán M; Sancho MP; Bayas JM; Gascón J; Costa J
    J Travel Med; 2009; 16(5):344-8. PubMed ID: 19796106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of hepatitis A virus in Mumbai, and immunogenicity and safety of hepatitis A vaccine.
    Dhawan PS; Shah SS; Alvares JF; Kher A; Shankaran ; Kandoth PW; Sheth PN; Kamath H; Kamath A; Koppikar GV; Kalro RH
    Indian J Gastroenterol; 1998 Jan; 17(1):16-8. PubMed ID: 9465507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening international travelers for hepatitis A antibodies versus routine vaccination: how generalizable are the results?
    Licciardone JC
    West J Med; 2000 Nov; 173(5):329-30. PubMed ID: 11069869
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effective analysis of hepatitis A prevention in Ireland.
    Rajan E; Shattock AG; Fielding JF
    Am J Gastroenterol; 2000 Jan; 95(1):223-6. PubMed ID: 10638588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: favourable cost-benefit ratio].
    Reintjes R; Bosman A; de Zwart O
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1777-80. PubMed ID: 10494329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and prevention of hepatitis A in travelers.
    Wu D; Guo CY
    J Travel Med; 2013; 20(6):394-9. PubMed ID: 24165384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide canadian study of hepatitis a antibody prevalence among children eight to thirteen years old.
    Duval B; De Serres G; Ochnio J; Scheifele D; Gîlca V
    Pediatr Infect Dis J; 2005 Jun; 24(6):514-9. PubMed ID: 15933561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of antibodies against hepatitis A (anti-HAV) in Singapore: the NFDD experience.
    Fock KM; Tay HH; Phua KB; Guan R; Chia SC; Chong R; Chee AE; Chew CN
    Singapore Med J; 1995 Feb; 36(1):26-7. PubMed ID: 7570129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis A vaccination coverage among adults 18-49 years traveling to a country of high or intermediate endemicity, United States.
    Lu PJ; Byrd KK; Murphy TV
    Vaccine; 2013 May; 31(19):2348-57. PubMed ID: 23523408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-Specific Anti-Hepatitis A Virus Seroepidemiology in Italian Travelers: Indications for Anti-Hepatitis A Vaccination.
    Castelli F; Carosi G; Tebaldi A; Pizzocolo G; Pisani S; Rossitto F; Boffelli L; Crevatin D; Pettoello R; Fausti G; Messino C; Brunelli M; Costa P; Ronca E
    J Travel Med; 1996 Dec; 3(4):214-218. PubMed ID: 9815459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.
    Bryan JP; Nelson M
    Arch Intern Med; 1994 Mar; 154(6):663-8. PubMed ID: 8129500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of vaccination against hepatitis A in travellers.
    Van Doorslaer E; Tormans G; Van Damme P
    J Med Virol; 1994 Dec; 44(4):463-9. PubMed ID: 7897383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and prevention of hepatitis A in travelers.
    Steffen R; Kane MA; Shapiro CN; Billo N; Schoellhorn KJ; van Damme P
    JAMA; 1994 Sep; 272(11):885-9. PubMed ID: 8078167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of hepatitis A virus antibody in a population aged 0-30 years in Shanghai, China: implications for hepatitis A immunization.
    Zhu Y; Yuan Z; Zhao Q; Chen G; Xu B
    Epidemiol Infect; 2013 Mar; 141(3):556-62. PubMed ID: 22687628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of hepatitis A virus in a cross-sectional study in Mexico: Implications for hepatitis A vaccination.
    Lazcano-Ponce E; Conde-Gonzalez C; Rojas R; DeAntonio R; Romano-Mazzotti L; Cervantes Y; Ortega-Barria E
    Hum Vaccin Immunother; 2013 Feb; 9(2):375-81. PubMed ID: 23291940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparities in hepatitis A virus (HAV) vaccination coverage among adult travelers to intermediate or high-risk countries: The role of birthplace and race/ethnicity.
    Narayanan N; Elsaid MI; NeMoyer RE; Trivedi N; Zeb U; Rustgi VK
    Vaccine; 2019 Jul; 37(30):4111-4117. PubMed ID: 31196682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine.
    Beck BR; Hatz CF; Loutan L; Steffen R
    J Travel Med; 2004; 11(4):201-6. PubMed ID: 15541221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.